Figure 4
Figure 4. PPAR-γ ligands decrease fLMP-induced phosphorylation of ERK-1/2 in human PMNs. PMNs were pretreated for 2 hours with or without troglitazone (Tro; 10 μM) or 15d-PGJ2 (PGJ2; 10 μM) before stimulation with 10−7 M fMLP. Cells were lysed at 0, 2, 10, and 30 minutes after fMLP treatment. Bio-Plex assay was then used to measure amounts of (A) phospho-ERK and (B) phospho-p38. Figures show the ratio of phosphorylated protein to the corresponding total protein. *P < .05 compared with DMSO (Ctrl) treated cells. Results are expressed as the average of 3 independent experiments performed in triplicate. Error bars represent SEM.

PPAR-γ ligands decrease fLMP-induced phosphorylation of ERK-1/2 in human PMNs. PMNs were pretreated for 2 hours with or without troglitazone (Tro; 10 μM) or 15d-PGJ2 (PGJ2; 10 μM) before stimulation with 10−7 M fMLP. Cells were lysed at 0, 2, 10, and 30 minutes after fMLP treatment. Bio-Plex assay was then used to measure amounts of (A) phospho-ERK and (B) phospho-p38. Figures show the ratio of phosphorylated protein to the corresponding total protein. *P < .05 compared with DMSO (Ctrl) treated cells. Results are expressed as the average of 3 independent experiments performed in triplicate. Error bars represent SEM.

Close Modal

or Create an Account

Close Modal
Close Modal